B cell lymphoma
Conditions
Interventions
Control group:R-CHOP/R-CDOP regimen (Rituximab, Cyclophosphamide, Hydroxyldaunorubicin/Liposome doxorubicin, Oncovin, Prednisone)
Experimental group:R-CHOP/R-CDOP (Rituximab, Cyclophosphamide, Hydroxyldaunorubicin/Liposome doxorubicin, Oncovin, Prednisone) Prophylactic treatment with SMZ
Sponsors
The First Affiliated Hospital, Zhejiang University College of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age>18 years old,= 6 months; 6. There is no organ dysfunction limiting the use of this protocol in the screening period; 7. Understand the research and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are unsuitable or cannot be treated with standard regimens due to economic constraints; 2. Patients who are allergic to the study drug; 3. Bilirubin>2mg/dL (35 umol/L), AST/ALT is more than twice the normal value, blood creatinine>177umol/L, creatinine clearance rate <60ml/min; 4. Chronic or active infectious diseases that require systemic antibiotics, antifungal drugs, or antiviral therapy; 5. Pregnant or breastfeeding women; 6. Other concurrent and uncontrolled by the investigator believes that it will affect the patient's medical condition participating in the study or other patients who are known or suspected to be unable to fully comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Pneumocystis jirovecii pneumonia; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactJin Jie/Yu Wenjuan
The First Affiliated Hospital, Zhejiang University College of Medicine
Outcome results
None listed